199 completed, 54 unknown, 22 terminated, 20 recruiting. 319 Phase 2, 63 Phase 1, 53 Phase 3.
Follow Atherosclerosis: new trials by email Literature Review of Atherosclerosis trials Research Report on Atherosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial Low-dose Colchicine at 0.5mg daily, Usual Care - Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-30 | 2026-11-04 |
| A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease VERVE-102, Placebo - Atherosclerosis, Cardiovascular Disease | Phase 2 | Recruiting | Verve Therapeutics, Inc. | 175 | 2026-09-24 | 2026-11-10 |
| A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Clazakizumab, Placebo - Atherosclerosis, Cardiovascular Disease | Phase 2 | Recruiting | Eli Lilly and Company | 120 | 2026-08-27 | 2026-11-03 |
| A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis YN001/Placebo 40mg, YN001/Placebo 20mg, YN001/Placebo 0mg - Atherosclerosis, Coronary Artery Disease | Phase 2 | Recruiting | Beijing Inno Medicine Co., Ltd. | 456 | 2026-07-31 | 2026-11-05 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events SAL0137 Dose 1, SAL0137 Dose 2, SAL0137 Dose 3 - Elevated Lipoprotein(a) | Phase 2 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2026-07-27 | 2026-07-27 |
| A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events Selnoflast, Placebo - Atherosclerosis | Phase 2 | Recruiting | Genentech, Inc. | 162 | 2026-06-05 | 2026-11-03 |
| Colchicine to Reduce Coronary Artery Inflammation in People With HIV Colchicine 0.5 mg, Placebo - HIV Infection, Cardiovascular Diseases (CVD) | Phase 2 | Recruiting | Instituto de Investigación Hospital Universitario La Paz | 90 | 2026-06-01 | 2026-07-15 |
| Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia CELULAS TRONCO, CONVENTIONAL DRESSING - Peripheral Arterial Disease, Leg Ulcer | Phase 1 / Phase 2 | Not yet recruiting | UPECLIN HC FM Botucatu Unesp | 40 | 2026-06-01 | 2026-05-06 |
| A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries. Sirolimus (RAPAMUNE) drug-coated balloon angioplasty catheter, Paclitaxel drug-coated balloon angioplasty - Popliteal Artery Disease, Superficial Femoral Artery Disease | Phase 2 / Phase 3 | Not yet recruiting | Concept Medical Inc. | 478 | 2026-04-01 | 2026-04-17 |
| TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men Pitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily - Erectile Dysfunction Due to Arterial Disease, Atheroscleroses | Phase 2 | Recruiting | Lomonosov Moscow State University Medical Research and Educational Center | 150 | 2026-03-05 | 2026-03-16 |
| Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis Low erythrodiol dose, Medium erythrodiol dose, High erythrodiol dose - Atherosclerosis Cardiovascular Disease | Phase 2 | Not yet recruiting | Spanish National Research Council | 22 | 2026-02-21 | 2026-02-19 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD TB-500, Placebo - Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1 / Phase 2 | Recruiting | Hudson Biotech | 80 | 2026-02-05 | 2026-11-12 |
| Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction YN001 20mg Dose + 5% glucose injection, 5% glucose injection - Atherosclerotic Cardiovascular Disease (ASCVD), Erectile Dysfunction | Phase 2 | Recruiting | Beijing Inno Medicine Co., Ltd. | 40 | 2026-02-04 | 2026-09-22 |
| Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, - Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | Aplagon Oy | 42 | 2026-01-29 | 2026-04-09 |
| A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease Yiyang Huoluo Decoction, conventional western medicine treatment - Coronary Heart Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Recruiting | Xia Liang | 30 | 2026-01-16 | 2026-03-25 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease Etribnabdione 25 mg BID, Etribnabdione 50 mg BID - Peripheral Arterial Disease | Phase 2 | Not yet recruiting | VivaCell Biotechnology España | 30 | 2026-01-01 | 2025-09-17 |
| A Study of DII235 in Adults With Elevated Lipoprotein(a) DII235, Saline - Lipoprotein Disorder | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 234 | 2025-12-02 | 2026-08-07 |
| Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Colchicine 0.5 MG Oral Tablet Once Daily, Placebo - Type 2 Diabetes Mellitus (T2DM), Atherosclerosis | Phase 2 | Recruiting | Tan Tock Seng Hospital | 300 | 2025-07-24 | 2026-09-24 |
| Effects of Carnosine In Patients With Peripheral Arterial Disease Patients Carnosine - Peripheral Arterial Disease | Phase 1 / Phase 2 | Recruiting | Shahid Baba | 144 | 2025-05-20 | 2025-05-29 |
Showing 20 of 319. Sign in to see all of them.
Peripheral Arterial Disease (123) · Chronic Limb-Threatening Ischemia (70) · Peripheral Vascular Diseases (40) · Cardiovascular Diseases (39) · Coronary Artery Disease (33) · Intermittent Claudication (28) · Inflammation (25) · Diabetes Mellitus (18) · Arterial Occlusive Diseases (15) · Dyslipidemias (15) · Vascular Diseases (15) · Ischemia (11) · Diabetes Mellitus, Type 2 (9) · Hypercholesterolemia (9)
Arteriosclerosis (317) · Arterial Occlusive Diseases (304) · Vascular Diseases (304) · Cardiovascular Diseases (280) · Pathological Conditions, Signs and Symptoms (148) · Peripheral Vascular Diseases (136) · Pathologic Processes (114) · Disease Attributes (77) · Chronic Disease (76) · Ischemia (71) · Nutritional and Metabolic Diseases (56) · Metabolic Diseases (52) · Peripheral Arterial Disease (50) · Myocardial Ischemia (41)
Clopidogrel (7) · Rosuvastatin Calcium (7) · Sodium Chloride (7) · Aspirin (6) · Colchicine (6) · Exercise (6) · Saline Solution (6) · Carnosine (4) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (4) · Standard of Care (4) · Ticagrelor (4) · apabetalone (4) · darapladib (4) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (3) · Atorvastatin (3)
National Heart, Lung, and Blood Institute (NHLBI) (12) · GlaxoSmithKline (8) · Flanders Medical Research Program (7) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (5) · Northwestern University (5) · Novartis Pharmaceuticals (5) · University of Southern California (5) · AnGes USA, Inc. (4) · Resverlogix Corp (4) · AstraZeneca (3) · Beijing Inno Medicine Co., Ltd. (3) · Brigham and Women's Hospital (3) · Daiichi Sankyo (3) · Eli Lilly and Company (3) · Emory University (3)
United States (153) · Germany (35) · Netherlands (28) · Canada (20) · United Kingdom (19) · Belgium (18) · China (18) · Spain (15) · Italy (13) · Japan (12) · France (11) · Denmark (10) · Russia (10) · Australia (9) · Brazil (8)
Marc Bosiers, MD (7) · Howard N. Hodis, MD (6) · Arshed Quyyumi, MD (3) · Mary McDermott, MD (3) · Antonio Chacon, MD, PhD (2) · Diego Martinez, MD, PhD (2) · Howard N. Hodis, M.D. (2) · Inmaculada Herrera, MD, PhD (2) · Marianne C Verhaar, MD, PhD (2) · Pieter Stella, MD (2)
PMID 42573020, PMID 35802393, PMID 35526057, PMID 29976553, PMID 36588397, PMID 37740111, PMID 38415744, PMID 39329200, PMID 11730394, PMID 12234947, PMID 12473676, PMID 12628952, PMID 1342820, PMID 16219100, PMID 16554527, PMID 17087620, PMID 17154704, PMID 17329508, PMID 18289548, PMID 18388929, PMID 18436114, PMID 18559703, PMID 18779447, PMID 19118243, PMID 19231633, PMID 19293413, PMID 19377384, PMID 19700099, PMID 19711453, PMID 19996872, PMID 20097752, PMID 20124733, PMID 20208057, PMID 20529449, PMID 20550691, PMID 20689074, PMID 21135365, PMID 21146749, PMID 21160056, PMID 21205939, PMID 21255957, PMID 21262998, PMID 21458008, PMID 21494228, PMID 21531233, PMID 21586692, PMID 21594960, PMID 21612611, PMID 21684715, PMID 21716303
2009 (4), R01HL095149 (2), 1RC2HL101515-01 (1), 2004 (1), 2005 (1), 2008 (1), 2016 (1), 2017 (1), 2019 (1), 2025 (1), K23HL169929 (1), P01AT002034 (1), P01HL059407 (1), P50HL083762 (1), R01AG013860 (1)